|
|
|
|
|
|
Chemotherapy: A large biotechnology company engaged Health Advances to investigate the market for two new chemotherapeutic agents, each of
which incorporated a marketed active ingredient in a novel formulation to reduce chemotherapy side effects. Through an extensive program of physician
interviews, we assessed the continuing role of the basic active ingredients in specific protocols for specific cancers in light of the emergence of
newer agents. We then assessed the potential impact of the new dosage forms on incremental use of the two active ingredients, and created a profile
of the market potential and recommendations regarding further development of the two agents.
Leukemia: Health Advances developed the sales and marketing strategy for a Phase III oncology product targeting selected leukemias. The
analysis considered the economics of building a salesforce versus partnering the drug with another biotech company or a pharmaceutical company with an
existing sales and marketing infrastructure.
Cellular Therapy: As part of merger discussions involving one of our clients, Health Advances investigated the potential for a novel cellular
therapy approach to a specific set of cancers. This project involved a technical understanding of the approach, an assessment of the unmet need based on
interviews with medical and surgical oncologists, and a projection of the product/service model that would likely be employed to make this treatment
approach realistic.
Pancreatic Cancer: Health Advances was asked to assist a biotech client in evaluating various clinical trial design options for its
therapeutic vaccine for pancreatic cancer in the US, Canada, and Australia. Health Advances defined disease progression and current standards of care
in each of the major pancreatic cancer patient segments, assessed the pros and cons of various trial designs, and estimated likely accrual rates for
the most attractive trial designs.
Predictive Cancer Diagnostic: Health Advances evaluated the potential for a predictive diagnostic to assist oncologists in making treatment
decisions for breast, colon, and lung cancer. Market potential was determined using a conjoint analysis as well as a survey to tie product preferences to
actual market share. A development strategy was performed based on the current status of the assay in different indications combined with necessary
attributes for market success in each patient population.
|
|
 |
|
|
|
|
